StreetSmart Live! Presents Michael Ballanger on 10/26/2020. Learn More

Streetwise Biotech / Pharmaceuticals Articles



Biopharma White Paper Posits FDA Approval of Biogen's Alzheimer's Drug Likely Next Month
Source: Streetwise Reports  (10/23/20)
ProMIS Neurosciences cites "unequivocally positive data" and encouraging FDA actions with respect to the therapeutic. More >


Biotech Secures Supplier of Psilocybin, Other Psychedelics
Source: Streetwise Reports  (10/21/20)
Revive Therapeutics will use these products in future studies and clinical trials. More >


Aptinyx Shares Trade 17% Higher on Positive Top-Line Data in Phase 2 PTSD Trial
Source: Streetwise Reports  (10/20/20)
Aptinyx shares set a new 52-week high price after the company reported statistically significant, top-line data from its Phase 2 Study of NYX-783 in patients diagnosed with post-traumatic stress disorder. More >


BioSpecifics Technologies Agrees to $658 Million Buyout Offer from Endo Pharmaceuticals
Source: Streetwise Reports  (10/19/20)
Biospecifics Technologies shares traded 45% higher after the company reported that it agreed to be acquired by Endo Pharmaceuticals for $88.50 per share in an all cash transaction. More >


With Bases Loaded, NervGen Swings for the Fences in Traumatic Brain Injury
Source: Dr. KSS, MD, PhD, for Streetwise Reports  (10/19/20)
Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of BioPub.co. More >


Organogenesis Shares Rise 20% on Q3 Net Revenue Growth and FY Guidance
Source: Streetwise Reports  (10/15/20)
Shares of Organogenesis Holdings traded higher after the company reported preliminary Q3/20 financial results demonstrating a 55% increase in year-over-year revenue. More >


Biopharma Announces Pulmonary Fibrosis Trial Now 25% Enrolled
Source: Streetwise Reports  (10/14/20)
Five sites in Australia and New Zealand are participating in this study of Algernon Pharmaceuticals' drug. More >


Life Sciences Firm Lands Record 4 Metric Tons Order for Antibiotic-Free Feedstock
Source: Streetwise Reports  (10/14/20)
Avivagen Inc. reported that it has received a record purchase order for its OxC-beta™ product from UNAHCO. More >


Phase 3 COVID-19 Study of Firm's Stem Cell Product Exceeds 50% Enrollment
Source: Streetwise Reports  (10/14/20)
The study design and goals and Mesoblast's next steps are reviewed in a Dawson James Securities report. More >


Altimmune Publishes Compelling Preclinical Data for Intranasal COVID-19 Vaccine Candidate
Source: Streetwise Reports  (10/13/20)
Altimmune Inc. shares traded 12% higher after the company published preclinical studies conducted together with the University of Alabama at Birmingham for AdCOVID, its intranasal COVID-19 vaccine candidate. More >


StreetSmart Live! Presents Algernon Pharmaceuticals
Source: Streetwise Reports  (10/8/20)
Algernon Pharmaceuticals CEO Christopher Moreau and guests fund manager Steve Palmer, Dr. Mark Swaim and Tony Pullen discuss the company's upcoming catalysts and events.
More >


Immunotherapy Firm Announces Positive Top-Line Trial Results for Severe and Critical COVID-19 Patients
Source: Streetwise Reports  (10/7/20)
The study data and potential near-term catalysts for Enlivex Therapeutics are covered in an H.C. Wainwright & Co. report. More >


Ocular Therapeutix Shares Rise 25% After Firm Reports 250% Sequential Increase in Q3 Revenue
Source: Streetwise Reports  (10/7/20)
Ocular Therapeutix shares reached a new 52-week high after the company reported that preliminary net product revenue increased to $5.8-5.9 million during Q3/20, representing a more than 250% increase over the previous quarter. More >


Biopharma's Multinational COVID-19 Study Hits 75% Enrollment Mark
Source: Streetwise Reports  (10/5/20)
Algernon Pharmaceuticals expects completion of the clinical trial next month and data readout by year-end. More >


MyoKardia Shares Don't Skip a Beat on $13.1 Billion Acquisition by Bristol Myers Squibb
Source: Streetwise Reports  (10/5/20)
Shares of MyoKardia traded 58% higher after the company reported that Bristol Myers Squibb has agreed to acquire the firm for $13.1 billion, or $225.00 per share in cash. More >


AMAG Pharma Receives $647 Million Takeover Bid from Luxembourg Firm
Source: Streetwise Reports  (10/1/20)
Shares of AMAG Pharmaceuticals traded 44% higher after the company reported it has agreed to be acquired by Covis Group S.à r.l. for $13.75 per share in cash, or approximately $498 million on a fully diluted basis. More >


Pharmaceutical Firm Completes Enrollment of 100 Patients in Phase 2b/3 COVID-19 Clinical Trial
Source: Streetwise Reports  (9/30/20)
Algernon Pharmaceuticals reported it has now enrolled 100 of 150 planned patients in its Phase 2b/3 human study of Ifenprodil for treatment of COVID-19. More >


Life Sciences Firm Finalizes First Sites for Phase 3 COVID-19 Trial
Source: Streetwise Reports  (9/30/20)
Enrollment for the study evaluating Revive Therapeutics' Bucillamine can now begin. More >


GENFIT and LabCorp Form Exclusive Partnership for Novel Liver Disease Diagnostic Test
Source: Streetwise Reports  (9/28/20)
GENFIT SA shares traded 30% higher after the company reported that it entered into an exclusive agreement with LabCorp to commercialize a novel diagnostic liver disease test. More >


Pharmaceutical Firm Reaches 50% Enrollment Mark in Phase 2b/3 Ifenprodil COVID-19 Study
Source: Streetwise Reports  (9/23/20)
Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2. More >


California-Based Biotech Receives COVID-19 Trial Clearance
Source: Streetwise Reports  (9/23/20)
The timeline and next steps for Equillium's proposed Phase 3 clinical study are outlined in an H.C. Wainwright & Co. report. More >


Biotech to Develop Alzheimer's Disease Vaccine Using Proprietary Peptide Antigens
Source: Streetwise Reports  (9/23/20)
ProMIS Neurosciences has demonstrated positive outcomes in proof-of-concept studies. More >


AIM ImmunoTech Achieves 200% Increase in Survival Results in Late-Stage Pancreatic Cancer Study
Source: Streetwise Reports  (9/22/20)
AIM ImmunoTech shares traded 20% higher after the firm reported it attained statistically significant, two-fold higher survival results in pancreatic cancer from research conducted at Erasmus University Medical Center in the Netherlands. More >


FDA Grants Ampio Pharma IND and Approves Phase 1 Trial for Inhaled Ampion in COVID-19 Patients
Source: Streetwise Reports  (9/21/20)
Ampio Pharmaceuticals traded 15% higher reaching a new 52-week high after the company reported that the U.S. FDA granted an IND and approved the clinical trial protocol for inhaled Ampion for use in COVID-19 patients with respiratory distress. More >


Biopharma Advances Development of Psilocybin-Based Therapeutics
Source: Streetwise Reports  (9/21/20)
Revive Therapeutics provides an update on its psychedelics therapeutics programs. More >


Showing Results: 1 to 25 of 1242 Next

Notable Quotes

"GCX announced that it plans to drill up to 1,500m at Stu."
– James Kwantes, Resource Opportunities
"VIPR's coffers have filled as result of warrant exercises."
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"FRE plans to drill about 1,500m at North Carlin."
– James Kwantes, Resource Opportunities

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"GOLD was approved to list and trade its shares on the NYSE American."
– Heiko Ihle, H.C. Wainwright & Co., Rodman & Renshaw
"DV's stepout hole DV20-211 cut 12.75m grading 351 g/t silver."
– Stuart McDougall, Mackie Research Capital
"WHN's Franz is a meaningful near-surface discovery."
– James Kwantes, Resource Opportunities